Moderna vaccine to be rolled out in April as UK aims to vaccinate all adults by July

  • March 29, 2021 06:37 PM BST
  • Abhijeet
    Financial Journalist Abhijeet
    132 Posts

    Abhijeet has a profound interest in capital markets. He writes on various developments from financial market-to-enterprise-to-economy. A day at work begins with analysing securities on the London Stock Exchange. A sharp eye for detail has been a ke...

Moderna vaccine to be rolled out in April as UK aims to vaccinate all adults by July

Source: insta_photos, Shutterstock


  • The UK authorities said that first jabs of Moderna vaccine would be rolled out in April.
  • The Boris Johnson government had said that it was committed to its plans to vaccinate the entire adult population by the end of July.

The UK government is confident that Moderna vaccine would soon be available to vaccinate the below 50 age population. Culture secretary Oliver Dowden said that he was sure that the first jabs of the Moderna vaccine would be rolled out in April.

The remarks from the authorities confirm pausing of the first dose programme. There have been reports that vaccination centres would have to temporarily close it next month onwards due to import delays. Vaccine deployment minister Nadhim Zahawi had tweeted that the UK government was committed to its plans to vaccinate the entire adult population by the end of July.

Also read: Astrazeneca’s Covid-19 Vaccine Efficient for Elders, Says UK Regulators

Moderna has been approved for use in the UK and would be the third vaccine that would be rolled out in the country after Pfizer and Oxford-AstraZeneca. The authorities had reported a shortage in vaccine supplies as a consignment of 5 million AstraZeneca vaccines was held up in India. Another 1.7 million does also need to be retested.

Authorities are, however, still doubtful about resuming international non-essential travel. Dowden said that every legal restriction might not end in June as it was hoped before after an adviser to the government expressed concerns about full relaxation plans.

One of the government’s advisors Professor Mark Woolhouse had told the BBC that he was unsure of the government’s complete relaxation plans 21 June onwards considering the prevailing situation.

Also read: EU To Ask the US to Export AstraZeneca/Oxford Vaccine: Report


                                             Copyright © 2021 Kalkine Media Pty Ltd.


The UK government has not yet confirmed how many doses of the vaccine would be delivered next month. However, media reports said that the initial supply would probably be 500,000. The probable recipients would be those in the age group between 40 and 49. Those above 50 years of age or have clinical complications or working in the NHS would receive either Pfizer or AstraZeneca vaccine.

Though authorities have been insisting on completing vaccination drive by July end, but supplies to the UK have been affected not only by issues in India, but also over a row with the European Union over exports. The bloc recently threatened to halt export of vaccines to the UK to secure doses for its own citizens. The EU had said that it had exported 10 million doses to the UK in six weeks but it did not receive doses from the UK.

Dowden said that he could guarantee that everyone would get their second dose of the vaccine within 12 weeks of the first. He said that the UK did not currently have a surplus of vaccines on being asked in an interview about UK’s plans to give Ireland 3.7 million jabs.

The UK’s biggest order book for vaccines is from AstraZeneca, which has promised to supply 100 million doses to the UK. Shares of AstraZeneca Plc (LON:AZN) were trading at GBX 7,359, up by 1.21 per cent on 29 March at 14:54 GMT+1.

Pfizer would be supplying another 40 million doses. Pfizer is the only vaccine which was used in the early stages of the vaccination drive.


The website is a service of Kalkine Media Ltd (Kalkine Media), Company Number 12643132. The principal purpose of the content on this website is to provide factual information only and does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. In providing you with the content on this website, we have not considered your objectives, financial situation or needs. You should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
Some of the images that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed on this website unless stated otherwise. The images that may be used on this website are taken from various sources on the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image. The information provided on the website is in good faith, however Kalkine Media does not make any representation or warranty regarding the content, accuracy, or use of the content on the website.



We have updated our Terms of Use, Privacy Policy & Cookie Policy. By continuing to use our website, you agree to these updates.

We use cookies on our site to analyze traffic and enhance your experience. For more information, visit our cookie policy and privacy policy.Okay